Literature DB >> 22244857

The number of patent tibial vessels does not influence primary patency after nitinol stenting of the femoral and popliteal arteries.

Jenny J Lee1, Steven G Katz.   

Abstract

OBJECTIVE: Initial TransAtlantic Inter-Society consensus (TASC) II classification has been shown to influence the patency of stented femoral and popliteal arteries. Although several studies have shown the effect of the number of runoff vessels on the durability of infrainguinal angioplasty without stenting, the influence of tibial vessel runoff on the patency of primarily stented femoral and popliteal arteries has not been as well defined. The purpose of this study was to determine whether the number of patent tibial vessels affects primary patency after primary stenting of the femoral and popliteal arteries.
METHODS: The records of all patients undergoing angioplasty and primary nitinol stenting of the femoral and popliteal arteries, by or under the supervision of one vascular surgeon, were reviewed. Results were analyzed by both the number of patent tibial vessels documented on periprocedural angiography and by using a modified Society for Vascular Surgery runoff score. TASC II classification was also recorded. Kaplan-Meier survival curves were plotted and differences between groups tested by log-rank method. Fisher exact and χ(2) tests were used to compare categoric factors.
RESULTS: During a 7-year period, 289 limbs in 236 patients underwent primary stenting of the femoral and popliteal arteries. Overall primary patency was 70.3% at 12 months, 52.4% at 24 months, and 39.1% at 36 months. Limbs classified as TASC A or B had significantly better patency rates than those classified as TASC C or D (P < .001). While the number of runoff vessels decreased with worsening of the TASC classification (P = .024), overall (P = .355), and within individual TASC classes (P ≥ .092 for each), there was no difference in the primary patency of stented segments with good runoff and those with compromised runoff. Limbs with poor runoff (one or no vessels) were no more likely to fail with occlusion than their counterparts with two or three patent tibial vessels (P = .383). The number of patent tibial vessels at the time of initial stenting did not impact ultimate limb salvage (P = .063).
CONCLUSIONS: The number of patent tibial vessels does not influence the primary patency of primarily stented femoral and popliteal arteries. TASC II classification appears to be significantly more predictive of initial failure after angioplasty and stenting of these vessels.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244857     DOI: 10.1016/j.jvs.2011.10.106

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

Review 1.  An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors.

Authors:  Nicolas W Shammas
Journal:  Int J Angiol       Date:  2013-03

2.  Impact of number of run-off vessels on interwoven nitinol mesh stents patency in the femoropopliteal segment.

Authors:  Gianluca Rigatelli; Marco Zuin; Fabio Dell'Avvocata; Dobrin Vassilev; Stefano Barison; Sabrina Osti; Alberto Mazza; Alberto Sacco
Journal:  J Geriatr Cardiol       Date:  2020-09-28       Impact factor: 3.327

3.  The factors affecting recurrence of symptoms after infrainguinal arterial endovascular angioplasty.

Authors:  Mi Ju Bae; Jong Geun Lee; Sung Woon Chung; Chung Won Lee; Chang Won Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-12-05

4.  Atrial Fibrillation is Associated with Femoropopliteal Totally Occlusive In-Stent Restenosis: A Single-Center, Retrospective, Observational Study.

Authors:  Yohsuke Honda; Keisuke Hirano; Masahiro Yamawaki; Motoharu Araki; Norihiro Kobayashi; Yasunari Sakamoto; Shinsuke Mori; Masakazu Tsutsumi; Kenji Makino; Shigemitsu Shirai; Masafumi Mizusawa; Takahiro Nakano; Yoshiaki Ito
Journal:  J Interv Cardiol       Date:  2021-02-03       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.